Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INI-4001 |
Synonyms | |
Therapy Description |
INI-4001 is a TLR7/8 agonist, which potentially enhances immune response (PMID: 38258117). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INI-4001 | INI 4001|INI4001 | TLR7 Agonist 12 TLR8 Agonist 9 | INI-4001 is a TLR7/8 agonist, which potentially enhances immune response (PMID: 38258117). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06302426 | Phase I | INI-4001 + Nivolumab Cemiplimab + INI-4001 INI-4001 + Pembrolizumab INI-4001 Atezolizumab + INI-4001 Avelumab + INI-4001 Durvalumab + INI-4001 | Trial of INI-4001 in Patients With Advanced Solid Tumours | Not yet recruiting | AUS | 0 |